The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Oncorena; Pfizer; Roche/Genentech
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche/Genentech
 
Michael B. Atkins
Honoraria - Merck
Consulting or Advisory Role - Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Exelixis; Fathom Biotechnology; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; Oncolys BioPharma; Pfizer; Pneuma Respiratory; Pyxis; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Camillo Porta
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD; Pfizer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; MSD; Novartis; Pfizer
Expert Testimony - EUSA Pharma; Pfizer
Travel, Accommodations, Expenses - Roche
 
Elena Verzoni
Consulting or Advisory Role - Janssen Oncology; Pfizer
Speakers' Bureau - Ipsen; Novartis
 
Michael N. Needle
Employment - AVEO
Leadership - AVEO
Stock and Other Ownership Interests - AVEO
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Brian I. Rini
Leadership - MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Peloton Therapeutics; Pfizer; Roche/Genentech; Surface Oncology; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer